Does the media favor TRVI or CTMX?

In the previous week, CytomX Therapeutics had 1 more articles in the media than Trevi Therapeutics. MarketBeat recorded 4 mentions for CytomX Therapeutics and 3 mentions for Trevi Therapeutics. Trevi Therapeutics' average media sentiment score of 1.35 beat CytomX Therapeutics' score of 1.18 indicating that Trevi Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Trevi Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CytomX Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to CTMX or NRIX?

In the previous week, Nurix Therapeutics had 18 more articles in the media than CytomX Therapeutics. MarketBeat recorded 22 mentions for Nurix Therapeutics and 4 mentions for CytomX Therapeutics. CytomX Therapeutics' average media sentiment score of 1.18 beat Nurix Therapeutics' score of 0.30 indicating that CytomX Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CytomX Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Nurix Therapeutics 3 Very Positive mention(s) 6 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media prefer CTMX or ABCL?

In the previous week, CytomX Therapeutics and CytomX Therapeutics both had 4 articles in the media. CytomX Therapeutics' average media sentiment score of 1.18 beat AbCellera Biologics' score of 0.70 indicating that CytomX Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CytomX Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive AbCellera Biologics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer NTLA or CTMX?

In the previous week, Intellia Therapeutics had 10 more articles in the media than CytomX Therapeutics. MarketBeat recorded 14 mentions for Intellia Therapeutics and 4 mentions for CytomX Therapeutics. CytomX Therapeutics' average media sentiment score of 1.18 beat Intellia Therapeutics' score of 0.44 indicating that CytomX Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Intellia Therapeutics 4 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral CytomX Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer KOD or CTMX?

In the previous week, Kodiak Sciences and Kodiak Sciences both had 4 articles in the media. CytomX Therapeutics' average media sentiment score of 1.18 beat Kodiak Sciences' score of 0.97 indicating that CytomX Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kodiak Sciences 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CytomX Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

CytomX Therapeutics (CTMX) Competitors

$3.70 -0.06 (-1.60%)

Closing price 07/13/2026 04:00 PM Eastern

Extended Trading

$3.75 +0.05 (+1.35%)

As of 04:08 AM Eastern

Compare

CTMX vs. TRVI, NRIX, ABCL, NTLA, and KOD

Should you buy CytomX Therapeutics stock or one of its competitors? MarketBeat compares CytomX Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with CytomX Therapeutics include Trevi Therapeutics (TRVI), Nurix Therapeutics (NRIX), AbCellera Biologics (ABCL), Intellia Therapeutics (NTLA), and Kodiak Sciences (KOD). These companies are all part of the "pharmaceutical products" industry.

How does CytomX Therapeutics compare to Trevi Therapeutics?

Trevi Therapeutics (NASDAQ:TRVI) and CytomX Therapeutics (NASDAQ:CTMX) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, earnings, risk, valuation, profitability, institutional ownership and dividends.

Trevi Therapeutics presently has a consensus price target of $22.67, indicating a potential upside of 37.21%. CytomX Therapeutics has a consensus price target of $12.10, indicating a potential upside of 227.03%. Given CytomX Therapeutics' higher possible upside, analysts clearly believe CytomX Therapeutics is more favorable than Trevi Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Trevi Therapeutics	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	3.00
CytomX Therapeutics	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.91

Trevi Therapeutics has a net margin of 0.00% compared to CytomX Therapeutics' net margin of -166.40%. Trevi Therapeutics' return on equity of -24.53% beat CytomX Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Trevi Therapeutics	N/A	-24.53%	-23.37%
CytomX Therapeutics	-166.40%	-36.61%	-28.02%

In the previous week, CytomX Therapeutics had 1 more articles in the media than Trevi Therapeutics. MarketBeat recorded 4 mentions for CytomX Therapeutics and 3 mentions for Trevi Therapeutics. Trevi Therapeutics' average media sentiment score of 1.35 beat CytomX Therapeutics' score of 1.18 indicating that Trevi Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Trevi Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CytomX Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

CytomX Therapeutics has higher revenue and earnings than Trevi Therapeutics. Trevi Therapeutics is trading at a lower price-to-earnings ratio than CytomX Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Trevi Therapeutics	N/A	N/A	-$42.76M	-$0.32	N/A
CytomX Therapeutics	$76.20M	8.26	-$17.37M	-$0.41	N/A

95.8% of Trevi Therapeutics shares are owned by institutional investors. Comparatively, 67.8% of CytomX Therapeutics shares are owned by institutional investors. 18.3% of Trevi Therapeutics shares are owned by insiders. Comparatively, 3.8% of CytomX Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Trevi Therapeutics has a beta of 1, indicating that its share price has a similar volatility profile to the broader market.Comparatively, CytomX Therapeutics has a beta of 2.08, indicating that its share price is 108% more volatile than the broader market.

Summary

Trevi Therapeutics beats CytomX Therapeutics on 9 of the 16 factors compared between the two stocks.

How does CytomX Therapeutics compare to Nurix Therapeutics?

CytomX Therapeutics (NASDAQ:CTMX) and Nurix Therapeutics (NASDAQ:NRIX) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, earnings, profitability, valuation, institutional ownership and risk.

CytomX Therapeutics has higher earnings, but lower revenue than Nurix Therapeutics. CytomX Therapeutics is trading at a lower price-to-earnings ratio than Nurix Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CytomX Therapeutics	$76.20M	8.26	-$17.37M	-$0.41	N/A
Nurix Therapeutics	$83.98M	28.06	-$264.46M	-$3.45	N/A

CytomX Therapeutics presently has a consensus price target of $12.10, indicating a potential upside of 227.03%. Nurix Therapeutics has a consensus price target of $34.08, indicating a potential upside of 50.05%. Given CytomX Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe CytomX Therapeutics is more favorable than Nurix Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CytomX Therapeutics	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.91
Nurix Therapeutics	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.79

CytomX Therapeutics has a beta of 2.08, indicating that its share price is 108% more volatile than the broader market. Comparatively, Nurix Therapeutics has a beta of 1.8, indicating that its share price is 80% more volatile than the broader market.

67.8% of CytomX Therapeutics shares are owned by institutional investors. 3.8% of CytomX Therapeutics shares are owned by company insiders. Comparatively, 6.7% of Nurix Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

CytomX Therapeutics has a net margin of -166.40% compared to Nurix Therapeutics' net margin of -928.44%. CytomX Therapeutics' return on equity of -36.61% beat Nurix Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CytomX Therapeutics	-166.40%	-36.61%	-28.02%
Nurix Therapeutics	-928.44%	-76.09%	-57.31%

In the previous week, Nurix Therapeutics had 18 more articles in the media than CytomX Therapeutics. MarketBeat recorded 22 mentions for Nurix Therapeutics and 4 mentions for CytomX Therapeutics. CytomX Therapeutics' average media sentiment score of 1.18 beat Nurix Therapeutics' score of 0.30 indicating that CytomX Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CytomX Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Nurix Therapeutics	3 Very Positive mention(s)	6 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Summary

CytomX Therapeutics beats Nurix Therapeutics on 11 of the 17 factors compared between the two stocks.

How does CytomX Therapeutics compare to AbCellera Biologics?

CytomX Therapeutics (NASDAQ:CTMX) and AbCellera Biologics (NASDAQ:ABCL) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, valuation, risk, profitability, media sentiment, analyst recommendations, earnings and institutional ownership.

CytomX Therapeutics currently has a consensus target price of $12.10, suggesting a potential upside of 227.03%. AbCellera Biologics has a consensus target price of $8.00, suggesting a potential upside of 22.70%. Given CytomX Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe CytomX Therapeutics is more favorable than AbCellera Biologics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CytomX Therapeutics	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.91
AbCellera Biologics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67

CytomX Therapeutics has a beta of 2.08, indicating that its stock price is 108% more volatile than the broader market. Comparatively, AbCellera Biologics has a beta of 1.14, indicating that its stock price is 14% more volatile than the broader market.

67.8% of CytomX Therapeutics shares are owned by institutional investors. Comparatively, 61.4% of AbCellera Biologics shares are owned by institutional investors. 3.8% of CytomX Therapeutics shares are owned by company insiders. Comparatively, 28.4% of AbCellera Biologics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

CytomX Therapeutics has higher revenue and earnings than AbCellera Biologics. AbCellera Biologics is trading at a lower price-to-earnings ratio than CytomX Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CytomX Therapeutics	$76.20M	8.26	-$17.37M	-$0.41	N/A
AbCellera Biologics	$75.13M	26.50	-$146.41M	-$0.48	N/A

CytomX Therapeutics has a net margin of -166.40% compared to AbCellera Biologics' net margin of -181.75%. AbCellera Biologics' return on equity of -14.86% beat CytomX Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CytomX Therapeutics	-166.40%	-36.61%	-28.02%
AbCellera Biologics	-181.75%	-14.86%	-10.62%

In the previous week, CytomX Therapeutics and CytomX Therapeutics both had 4 articles in the media. CytomX Therapeutics' average media sentiment score of 1.18 beat AbCellera Biologics' score of 0.70 indicating that CytomX Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CytomX Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
AbCellera Biologics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

CytomX Therapeutics beats AbCellera Biologics on 11 of the 15 factors compared between the two stocks.

How does CytomX Therapeutics compare to Intellia Therapeutics?

Intellia Therapeutics (NASDAQ:NTLA) and CytomX Therapeutics (NASDAQ:CTMX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, valuation, profitability, dividends, analyst recommendations, earnings, institutional ownership and risk.

CytomX Therapeutics has higher revenue and earnings than Intellia Therapeutics. CytomX Therapeutics is trading at a lower price-to-earnings ratio than Intellia Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Intellia Therapeutics	$67.67M	26.88	-$412.69M	-$3.54	N/A
CytomX Therapeutics	$76.20M	8.26	-$17.37M	-$0.41	N/A

Intellia Therapeutics has a beta of 1.77, indicating that its stock price is 77% more volatile than the broader market. Comparatively, CytomX Therapeutics has a beta of 2.08, indicating that its stock price is 108% more volatile than the broader market.

Intellia Therapeutics presently has a consensus price target of $20.67, suggesting a potential upside of 58.79%. CytomX Therapeutics has a consensus price target of $12.10, suggesting a potential upside of 227.03%. Given CytomX Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe CytomX Therapeutics is more favorable than Intellia Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Intellia Therapeutics	3 Sell rating(s)	10 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.35
CytomX Therapeutics	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.91

88.8% of Intellia Therapeutics shares are owned by institutional investors. Comparatively, 67.8% of CytomX Therapeutics shares are owned by institutional investors. 3.5% of Intellia Therapeutics shares are owned by insiders. Comparatively, 3.8% of CytomX Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

CytomX Therapeutics has a net margin of -166.40% compared to Intellia Therapeutics' net margin of -597.04%. CytomX Therapeutics' return on equity of -36.61% beat Intellia Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Intellia Therapeutics	-597.04%	-57.47%	-46.24%
CytomX Therapeutics	-166.40%	-36.61%	-28.02%

In the previous week, Intellia Therapeutics had 10 more articles in the media than CytomX Therapeutics. MarketBeat recorded 14 mentions for Intellia Therapeutics and 4 mentions for CytomX Therapeutics. CytomX Therapeutics' average media sentiment score of 1.18 beat Intellia Therapeutics' score of 0.44 indicating that CytomX Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Intellia Therapeutics	4 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
CytomX Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

CytomX Therapeutics beats Intellia Therapeutics on 11 of the 15 factors compared between the two stocks.

How does CytomX Therapeutics compare to Kodiak Sciences?

Kodiak Sciences (NASDAQ:KOD) and CytomX Therapeutics (NASDAQ:CTMX) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, profitability, valuation, media sentiment, analyst recommendations, earnings, risk and institutional ownership.

89.1% of Kodiak Sciences shares are owned by institutional investors. Comparatively, 67.8% of CytomX Therapeutics shares are owned by institutional investors. 44.4% of Kodiak Sciences shares are owned by company insiders. Comparatively, 3.8% of CytomX Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Kodiak Sciences currently has a consensus target price of $42.14, suggesting a potential upside of 2.54%. CytomX Therapeutics has a consensus target price of $12.10, suggesting a potential upside of 227.03%. Given CytomX Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe CytomX Therapeutics is more favorable than Kodiak Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kodiak Sciences	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
CytomX Therapeutics	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.91

CytomX Therapeutics has higher revenue and earnings than Kodiak Sciences. Kodiak Sciences is trading at a lower price-to-earnings ratio than CytomX Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kodiak Sciences	N/A	N/A	-$229.97M	-$4.17	N/A
CytomX Therapeutics	$76.20M	8.26	-$17.37M	-$0.41	N/A

Kodiak Sciences has a beta of 2.19, indicating that its share price is 119% more volatile than the broader market. Comparatively, CytomX Therapeutics has a beta of 2.08, indicating that its share price is 108% more volatile than the broader market.

In the previous week, Kodiak Sciences and Kodiak Sciences both had 4 articles in the media. CytomX Therapeutics' average media sentiment score of 1.18 beat Kodiak Sciences' score of 0.97 indicating that CytomX Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kodiak Sciences	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CytomX Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Kodiak Sciences has a net margin of 0.00% compared to CytomX Therapeutics' net margin of -166.40%. CytomX Therapeutics' return on equity of -36.61% beat Kodiak Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kodiak Sciences	N/A	-253.85%	-81.48%
CytomX Therapeutics	-166.40%	-36.61%	-28.02%

Summary

CytomX Therapeutics beats Kodiak Sciences on 11 of the 15 factors compared between the two stocks.

Get CytomX Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CTMX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CTMX vs. The Competition

Export

Metric	CytomX Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$639.90M	$3.71B	$7.05B	$12.61B
Dividend Yield	N/A	2.20%	2.68%	8.00%
P/E Ratio	-9.02	20.85	27.13	24.26
Price / Sales	8.26	314.01	589.11	117.88
Price / Cash	N/A	61.98	29.22	49.36
Price / Book	6.38	8.49	10.77	6.29
Net Income	-$17.37M	$23.83M	$3.58B	$330.66M
7 Day Performance	-3.65%	-3.56%	-2.10%	-1.32%
1 Month Performance	22.92%	6.31%	3.29%	-0.64%
1 Year Performance	54.81%	48.30%	26.34%	19.08%

CytomX Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CTMX CytomX Therapeutics	2.5529 of 5 stars	$3.70 -1.6%	$12.10 +227.0%	+52.9%	$639.90M	$76.20M	N/A	170	News Coverage
TRVI Trevi Therapeutics	3.4732 of 5 stars	$17.95 +0.1%	$22.67 +26.3%	+152.2%	$2.55B	N/A	N/A	20	News Coverage
NRIX Nurix Therapeutics	3.5387 of 5 stars	$24.04 +0.3%	$32.20 +33.9%	+82.6%	$2.48B	$83.98M	N/A	300	Earnings Report Analyst Upgrade
ABCL AbCellera Biologics	2.1547 of 5 stars	$7.87 -3.0%	$7.80 -0.9%	+62.6%	$2.48B	$75.13M	N/A	500	Gap Down
NTLA Intellia Therapeutics	3.2428 of 5 stars	$17.84 +1.6%	$20.46 +14.7%	+12.9%	$2.45B	$67.67M	N/A	600	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CTMX) was last updated on 7/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

CytomX Therapeutics (CTMX) Competitors

CTMX vs. TRVI, NRIX, ABCL, NTLA, and KOD

How does CytomX Therapeutics compare to Trevi Therapeutics?

Summary

How does CytomX Therapeutics compare to Nurix Therapeutics?

Summary

How does CytomX Therapeutics compare to AbCellera Biologics?

Summary

How does CytomX Therapeutics compare to Intellia Therapeutics?

Summary

How does CytomX Therapeutics compare to Kodiak Sciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CTMX vs. The Competition

CytomX Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

CytomX Therapeutics (CTMX) Competitors

CTMX vs. TRVI, NRIX, ABCL, NTLA, and KOD

How does CytomX Therapeutics compare to Trevi Therapeutics?

Do analysts recommend TRVI or CTMX?

Is TRVI or CTMX more profitable?

Does the media favor TRVI or CTMX?

Which has higher valuation and earnings, TRVI or CTMX?

Do institutionals and insiders believe in TRVI or CTMX?

Which has more risk & volatility, TRVI or CTMX?

Summary

How does CytomX Therapeutics compare to Nurix Therapeutics?

Which has preferable earnings & valuation, CTMX or NRIX?

Do analysts prefer CTMX or NRIX?

Which has more volatility & risk, CTMX or NRIX?

Do institutionals & insiders believe in CTMX or NRIX?

Is CTMX or NRIX more profitable?

Does the media refer more to CTMX or NRIX?

Summary

How does CytomX Therapeutics compare to AbCellera Biologics?

Do analysts recommend CTMX or ABCL?

Which has more volatility & risk, CTMX or ABCL?

Do institutionals and insiders hold more shares of CTMX or ABCL?

Which has better earnings and valuation, CTMX or ABCL?

Is CTMX or ABCL more profitable?

Does the media prefer CTMX or ABCL?

Summary

How does CytomX Therapeutics compare to Intellia Therapeutics?

Which has higher valuation and earnings, NTLA or CTMX?

Which has more volatility and risk, NTLA or CTMX?

Do analysts recommend NTLA or CTMX?

Do insiders and institutionals hold more shares of NTLA or CTMX?

Is NTLA or CTMX more profitable?

Does the media prefer NTLA or CTMX?

Summary

How does CytomX Therapeutics compare to Kodiak Sciences?

Do insiders & institutionals hold more shares of KOD or CTMX?

Do analysts recommend KOD or CTMX?

Which has stronger earnings & valuation, KOD or CTMX?

Which has more risk & volatility, KOD or CTMX?

Does the media prefer KOD or CTMX?

Is KOD or CTMX more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CTMX vs. The Competition

CytomX Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools